Chemoradiotherapy for Recurrent T1G3 Bladder Cancer After BCG Failure
试验速览
- 阶段
- 4 期
- 入组人数
- 20
- 主要终点
- Result of chemoradiation for recurrentT1G3 BC after BCG failure
研究概览
简要总结
To evaluate the short term results of chemoradiation in case of T1G3 BC after BCG failure.
详细描述
Non- muscle invasive bladder cancer (NMIBC) is a heterogeneous group of cancers. For most urologists the treatment of T1G3 tumor poses a dilemma of management.The spectrum of clinical behavior includes; T1 lesions that will not progress however T1G3 may be potentially lethal, associated with metastatic disease at the time of presentation.
The major goal of treatment for T1G3 BC should be bladder preservation whenever possible.
Intravesical therapy with Bacille Calmette Guerin (BCG) may decrease the recurrence rate by compared with transurethral resection of bladder tumor (TURBT) alone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients with recurrent T1G3 bladder cancer after 6 doses of BCG consenting for chemoradiation and refusing radical cystectomy
排除标准
- •Any patients with distant metastasis or positive LN on CT or MRI.
- •Patients unfit for chemoradiation
研究组 & 干预措施
chemoradiotherapy
Chemoradiation in the form of cisplatin plus conformal radiotherapy 55GY/20 fractions which is biologically effective to 64GY/32 fractions fr
干预措施: chemoradiation (Combination Product)
结局指标
主要结局
Result of chemoradiation for recurrentT1G3 BC after BCG failure
时间窗: followup within two years
treatment of 20 patients with recurrent T1G3 BC by chemoradiation to see efficacy and safety .and to reduce the number of recurrent cases and improve survival.
次要结局
未报告次要终点
研究者
MokhtarDawood
Assistant Lecturer of Urology
Assiut University